Investor Presentaiton
R&D investor presentation
The phase 2 trial investigated semaglutide in the treatment of
NASH
Semaglutide NASH phase 2 trial design
Baseline characteristics
Semaglutide 0.1 mg s.c. OD
Sema
0.1 mg OD 0.2mg OD 0.4mg OD
Sema
Sema
Placebo
320 patients
Semaglutide 0.2 mg s.c. OD
Number of patients
80
78
82
80
with NASH
fibrosis stage
1, 2, 31
Age (years)
55.2
58.1
54.3
52.4
Semaglutide 0.4 mg s.c. OD
Type 2 diabetes (%)
49
51
49
50
Placebo 0.1 mg, 0.2 mg or 0.4 mg
Body weight
98.4
97.1
96.6
101.3
72 week treatment
BMI (kg/m²)
36.1
35.6
35.2
36.1
BMI classification (%)
Primary endpoint
< 25
1.3
0
2.4
1.3
•
Resolution of NASH and no worsening in liver fibrosis
25 to 30
18.8
23.1
20.7
17.5
30 to
35≤
35
25.0
26.9
30.5
26.3
55.0
50.0
46.3
55.0
¹Full list of inclusion criteria: Age 18-75; NASH activity score ≥ 4; NASH fibrosis stage 1,2,3; BMI> 25.0 kg/m2, HbA1c 10%; No other chronic liver disease other than NASH
NASH: Non-alcoholic steatohepatitis; s.c.: subcutaneous; OD: once-daily
17View entire presentation